bs-2900R [Primary Antibody]
JNK1/2 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: JNK1/2

Specificity: There is a 71% chance that this antibody will cross-react with MAPK10(JNK3) if in the same tissue.

Immunogen Range: 311-424/424


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 5601

Swiss Prot: P45984

Source: KLH conjugated synthetic peptide derived from human JNK2

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death. Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK9/JNK2. In turn, MAPK9/JNK2 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional activity. In response to oxidative or ribotoxic stresses, inhibits rRNA synthesis by phosphorylating and inactivating the RNA polymerase 1-specific transcription initiation factor RRN3. Promotes stressed cell apoptosis by phosphorylating key regulatory factors including TP53 and YAP1. In T-cells, MAPK8 and MAPK9 are required for polarized differentiation of T-helper cells into Th1 cells. Upon T-cell receptor (TCR) stimulation, is activated by CARMA1, BCL10, MAP2K7 and MAP3K7/TAK1 to regulate JUN protein levels. Plays an important role in the osmotic stress-induced epithelial tight-junctions disruption. When activated, promotes beta-catenin/CTNNB1 degradation and inhibits the canonical Wnt signaling pathway. Participates also in neurite growth in spiral ganglion neurons. MAPK9 isoforms display different binding patterns: alpha-1 and alpha-2 preferentially bind to JUN, whereas beta-1 and beta-2 bind to ATF2. However, there is no correlation between binding and phosphorylation, which is achieved at about the same efficiency by all isoforms. JUNB is not a substrate for JNK2 alpha-2, and JUND binds only weakly to it.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 48


Cross Reactive Species: Human
Mouse
Rat

Predicted Cross Reactive Species: Dog
Cow
Pig
Horse
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Ji X et al. Double-component diazeniumdiolate derivatives as anti-cancer agents. Bioorg Med Chem. 2020 Apr 15;28(8):115405.Read more>>
VALIDATION IMAGES

Formalin-fixed and paraffin embedded human scalp labeled with Rabbit Anti JNK2 Polyclonal Antibody, Unconjugated (bs-2900R) at 1:200 followed by conjugation to the secondary antibody and DAB staining


Formalin-fixed and paraffin embedded human skin labeled with Rabbit Anti JNK2 Polyclonal Antibody, Unconjugated (bs-2900R) at 1:200 followed by conjugation to the secondary antibody and DAB staining


Formalin-fixed and paraffin embedded rat brain labeled with Rabbit Anti JNK2 Polyclonal Antibody, Unconjugated (bs-2900R) at 1:200 followed by conjugation to the secondary antibody and DAB staining


Lane 1: Hela cell lysates; Lane 2: Mouse uterus lysates probed with JNK1/2 Polyclonal Antibody, Unconjugated (bs-2900R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.


Lane 1: Mouse NIH/3T3 cell lysates; Lane 2: Mouse Cerebrum tissue lysates; Lane 3: Mouse Heart tissue lysates; Lane 4: Rat Cerebrum tissue lysates probed with JNK2/MAPK9 Polyclonal Antibody, Unconjugated (bs-2900R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.